Elevance Health Files Definitive Proxy Statement

Ticker: ELV · Form: DEF 14A · Filed: Mar 29, 2024 · CIK: 1156039

Sentiment: neutral

Topics: Elevance Health, DEF 14A, Proxy Statement, Shareholder Meeting, Executive Compensation

TL;DR

<b>Elevance Health has filed its Definitive Proxy Statement for the 2023 fiscal year.</b>

AI Summary

Elevance Health, Inc. (ELV) filed a Proxy Statement (DEF 14A) with the SEC on March 29, 2024. Elevance Health, Inc. filed a Definitive Proxy Statement (DEF 14A) on March 29, 2024. The filing covers the period from January 1, 2023, to December 31, 2023. The company was formerly known as Anthem, Inc. and WellPoint, Inc. Elevance Health is incorporated in Indiana. The filing includes details on various equity and pension adjustments for PEO and Non-PEO members.

Why It Matters

For investors and stakeholders tracking Elevance Health, Inc., this filing contains several important signals. This filing provides shareholders with crucial information regarding upcoming shareholder meetings, executive compensation, and voting matters. Understanding the details within the proxy statement is essential for shareholders to make informed decisions about their investments and company governance.

Risk Assessment

Risk Level: low — Elevance Health, Inc. shows low risk based on this filing. The filing is a routine DEF 14A, indicating standard corporate governance and disclosure practices without immediate financial or operational red flags.

Analyst Insight

Shareholders should review the proxy statement for details on executive compensation, board nominations, and any proposed corporate actions to exercise their voting rights effectively.

Key Numbers

Key Players & Entities

FAQ

When did Elevance Health, Inc. file this DEF 14A?

Elevance Health, Inc. filed this Proxy Statement (DEF 14A) with the SEC on March 29, 2024.

What is a DEF 14A filing?

A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by Elevance Health, Inc. (ELV).

Where can I read the original DEF 14A filing from Elevance Health, Inc.?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Elevance Health, Inc..

What are the key takeaways from Elevance Health, Inc.'s DEF 14A?

Elevance Health, Inc. filed this DEF 14A on March 29, 2024. Key takeaways: Elevance Health, Inc. filed a Definitive Proxy Statement (DEF 14A) on March 29, 2024.. The filing covers the period from January 1, 2023, to December 31, 2023.. The company was formerly known as Anthem, Inc. and WellPoint, Inc..

Is Elevance Health, Inc. a risky investment based on this filing?

Based on this DEF 14A, Elevance Health, Inc. presents a relatively low-risk profile. The filing is a routine DEF 14A, indicating standard corporate governance and disclosure practices without immediate financial or operational red flags.

What should investors do after reading Elevance Health, Inc.'s DEF 14A?

Shareholders should review the proxy statement for details on executive compensation, board nominations, and any proposed corporate actions to exercise their voting rights effectively. The overall sentiment from this filing is neutral.

How does Elevance Health, Inc. compare to its industry peers?

Elevance Health operates within the hospital and medical service plans industry, providing health insurance and related services.

Are there regulatory concerns for Elevance Health, Inc.?

The filing is made under the Securities Exchange Act of 1934, specifically Section 14(a), which governs the solicitation of proxies.

Industry Context

Elevance Health operates within the hospital and medical service plans industry, providing health insurance and related services.

Regulatory Implications

The filing is made under the Securities Exchange Act of 1934, specifically Section 14(a), which governs the solicitation of proxies.

What Investors Should Do

  1. Review the executive compensation details to understand pay structures and potential incentives.
  2. Examine board member nominations and qualifications for governance insights.
  3. Note any shareholder proposals and the company's recommended voting actions.

Year-Over-Year Comparison

This is a DEF 14A filing, which is a standard annual disclosure for proxy statements, indicating routine corporate governance reporting.

Filing Stats: 4,420 words · 18 min read · ~15 pages · Grade level 16.3 · Accepted 2024-03-29 16:08:12

Key Financial Figures

Filing Documents

Executive Compensation

Executive Compensation 39 Proposal 2 – Advisory Vote to Approve the Compensation of Our Named Executive Officers 39 Compensation Discussion & Analysis 40 Executive Summary 40 Compensation Decision-Making Process 44 Elements of Total Rewards 47 Primary Components of 202 3 Target Compensation 47 202 3 Compensation Decisions 48 Compensation Policies and Practices 56 Compensation and Talent Committee Report 57 Compensation Tables 57 Summary Compensation Table 57 Grants of Plan-Based Awards 59 Outstanding Equity Awards at Fiscal Year-End 60 Option Exercises and Stock Vested 62 Pension Benefits 63 Non-Qualified Deferred Compensation 63 Potential Payments Upon Termination 64 CEO Pay Ratio 67 Pay versus Performance 68 Audit Committee Matters 70 Proposal 3 – Ratification of the Appointment of Independent Registered Public Accounting Firm 70 The Audit Committee's Consideration of Independence of Independent Registered Public Accounting Firm 71 Independent Registered Public Accounting Firm's Fees 71 Audit Committee Pre-Approval Policy 71 Audit Committee Report 72 Proposal 4 – Shareholder Proposal to Adopt a Policy to Require Certain Third-Party Organizations to Annually Report Political Activity Expenditures Prior to Elevance Health Donating to the Organizations. 73

Security Ownership of Certain Beneficial Owners and Management

Security Ownership of Certain Beneficial Owners and Management 76 Stock Held by 5% or More Beneficial Owners 76 Stock Held by Directors, Nominees and Executive Officers 77 Information on Voting and the Annual Meeting 78 Annex A – Elevance Health , Inc. GAAP Reconciliation 84 2024 Proxy Statement 3 Table of Contents Proxy Summary This summary highlights selected information in this Proxy Statement. Please review the entire Proxy Statement before voting. We also encourage you to read our Annual Report on Form 10-K for the year ended December 31, 2023 (our "Form 10-K") before voting. For the reasons set forth below and as further detailed throughout this Proxy Statement, the Board of Directors recommends that you vote as follows for each of the proposals: FOR each nominee Page 11 Proposal 1 Election of Directors Three directors have been nominated for election to hold office for a term to expire at the 2027 Annual Meeting: Lewis Hay, III Antonio F. Neri Ramiro G. Peru FOR Page 39 Proposal 2 Advisory Vote to Approve the Compensation of Our Named Executive Officers Our executive compensation program (the "Total Rewards" program) is designed to attract, engage, motivate and retain a talented team of executive officers and to appropriately reward those executive officers for their contributions to our business, our consumers and our shareholders. This proposal gives our shareholders the opportunity to express their views on the compensation of our Named Executive Officers ("Say-on-Pay"). FOR Page 70 Proposal 3 Ratification of the Appointment of Independent Registered Public Accounting Firm The Audit Committee has selected Ernst & Young LLP to continue serving as our independent registered public accounting firm for the year ending December 31, 2024. AGAINST the Shareholder Proposal Page 73 Proposal 4 One Prop osal was Subm itted by Shareholders Shareholder Proposal to Adopt a Policy to Require Certain Third-Party Organiz

View Full Filing

View this DEF 14A filing on SEC EDGAR

View on Read The Filing